Przedsiębiorstwo Farmaceutyczne ApeximS.A.

Dispensing chemist in specialised stores

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2002-02-13
Share capital
77 700 000,00 PLN
Activity description

Przedsiębiorstwo Farmaceutyczne Apexim S.A. is a pharmaceutical company based in Łódź at ul. Kinga C. Gillette 11. The excerpt lists the company’s registration details, including KRS 89677, NIP 896-11-71-623, and share capital of PLN 77,700,000, fully paid up.

Registered address
Kinga C. Gillette 11, 94-406 Łódź, Poland
Website
apexim-sa.plWebsite active
Electronic delivery address
AE:PL-56172-52355-VFRJF-19

Financials

Revenue history (in m)

Financial insight

  • Possible Estonian CIT: Equity includes Art. 28d line items, but all amounts are 0 – this may be an accounting template or the first year of the regime.

Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue
This companyUSD 40.17mMedianUSD 1.75mAverageUSD 5.00m
Net profit
This companyUSD 4.82mMedianUSD 17.49kAverageUSD 85.24k
Operating costs
This companyUSD 34.89mMedianUSD 1.72mAverageUSD 4.85m
Assets
This companyUSD 33.88mMedianUSD 495.38kAverageUSD 1.71m

Bank accounts

Registered as a VAT taxpayer on 2003-12-31. Active

Debt

No entries in the National Debtors Register (KRZ). No proceedings in KRZ

Real estate

TypeAmount
Buildings and premises
PLN 282.7K

Public aid

No public aid cases recorded in the last 10 years.

Tenders

No recorded participation in tenders.

Public sector contracts

Przedsiębiorstwo Farmaceutyczne Apexim is the contractor in 2 public sector contracts, worth PLN 1.01k in total. They were signed with 2 public buyers.

Public buyerValue
Szkoła Podstawowa Nr 8 Im. Noblistów Polskich w OleśnicyPLN 409.44
Szkoła Podstawowa Nr 64 Im. Władysława BroniewskiegoPLN 605.50

National Health Fund (NFZ) contracts

Przedsiębiorstwo Farmaceutyczne Apexim has been an NFZ healthcare provider since 2016. In 2026 it is performing 11 contracts with a total value of USD 823.88. All its contracts were worth USD 3.43k in total.

NFZ contract value by year (USD)

Type of careNFZ branchContractsValue in 2026
Programy pilotażowełódzkie2USD 823.88
Inne usługi realizowane w aptekachdolnośląskie5USD 0.00
Inne usługi realizowane w aptekachłódzkie1USD 0.00
Inne usługi realizowane w aptekachmazowieckie1USD 0.00
Inne usługi realizowane w aptekachopolskie1USD 0.00

Trademarks

Przedsiębiorstwo Farmaceutyczne Apexim currently holds no active trademarks with the Polish Patent Office. 2 marks have expired or were not registered. The first mark was filed in 1999.

MarkProtected until
APTEKA–
.APEXIM.–

Authorized Representatives

Aleksandra Olszacka – Vice President of the Management Board
Bożena Helena Szymańska – President of the Management Board
Katarzyna Nockowska Stańczak – Vice President of the Management Board

Manner of representation

If a multi-member management board is appointed, the joint action of two members of the management board or one member of the management board jointly with a commercial proxy is required for the validity of declarations made on behalf of the company.

Supervisory board

Andrzej Gawryś – Supervisory Board Member
Ewa Wasiak Zasada – Supervisory Board Member
Jarosław Piotr Strzecha – Supervisory Board Member

Ownership

OwnerSharesShare valueStake
77,700,000$20,988,654.78100%

Beneficial owners

Person

Subsidiaries

NameStake
Orion Tradingsp. z o.o.
76%
Ardea Polskasp. z o.o.
75.9615%
Apteka Jfmsp. z o.o.
75.9259%

Competitors

Name
Przedsiębiorstwo Produkcyjno-Handlowe Apimexsp. z o.o.
APIS Farmacjasp. z o.o.
Farmjugsp. z o.o.
Farmjug Agsp. z o.o.
Adpharmasp. z o.o.

Change history

DateEvent
2018-05-17Share capital change
2014-09-12Address change
2008-08-25Address change
2008-05-29Share capital change
2007-06-27Share capital change

FAQ

Last updated: 2026-06-09